{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(11)"],"submitter":["Ryad N"],"pubmed_abstract":["<b>Aim:</b> Using molecular hybridization approach, novel 18 quinoline derivatives (<b>6a-11</b>) were designed and synthesized as EGFR-TK inhibitors. <b>Materials & methods:</b> The antiproliferative activity was assessed against breast (MCF-7), leukemia (HL-60) and lung (A549) cancer cell lines. Moreover, the most active quinoline derivatives (<b>6d</b> and <b>8b</b>) were further investigated for their potential as EGFR-TK inhibitors. In addition, cell cycle analysis and apoptosis induction activity were conducted. <b>Results:</b> A considerable cytotoxic activity was attained with IC<sub>50</sub> values spanning from 0.06 to 1.12 μM. Besides, the quinoline derivatives <b>6d</b> and <b>8b</b> displayed potent inhibitory activity against EFGR with IC<sub>50</sub> values of 0.18 and 0.08 μM, respectively. <b>Conclusion:</b> Accordingly, the afforded quinoline derivatives can be used as promising lead anticancer candidates for future optimization."],"journal":["Future medicinal chemistry"],"pagination":["1087-1107"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11216632"],"repository":["biostudies-literature"],"pubmed_title":["Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment."],"pmcid":["PMC11216632"],"pubmed_authors":["Saleem RM","Elmaaty AA","Zaki I","Ahmed Maghrabi AH","Ryad N","M Ibrahim I","Yahya Alahdal MA","Ghany LMAA"],"additional_accession":[]},"is_claimable":false,"name":"Harnessing molecular hybridization approach to discover novel quinoline EGFR-TK inhibitors for cancer treatment.","description":"<b>Aim:</b> Using molecular hybridization approach, novel 18 quinoline derivatives (<b>6a-11</b>) were designed and synthesized as EGFR-TK inhibitors. <b>Materials & methods:</b> The antiproliferative activity was assessed against breast (MCF-7), leukemia (HL-60) and lung (A549) cancer cell lines. Moreover, the most active quinoline derivatives (<b>6d</b> and <b>8b</b>) were further investigated for their potential as EGFR-TK inhibitors. In addition, cell cycle analysis and apoptosis induction activity were conducted. <b>Results:</b> A considerable cytotoxic activity was attained with IC<sub>50</sub> values spanning from 0.06 to 1.12 μM. Besides, the quinoline derivatives <b>6d</b> and <b>8b</b> displayed potent inhibitory activity against EFGR with IC<sub>50</sub> values of 0.18 and 0.08 μM, respectively. <b>Conclusion:</b> Accordingly, the afforded quinoline derivatives can be used as promising lead anticancer candidates for future optimization.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-02T20:46:53.676Z","creation":"2026-04-20T03:14:21.784Z"},"accession":"S-EPMC11216632","cross_references":{"pubmed":["38722235"],"doi":["10.1080/17568919.2024.2342201"]}}